Ondansetron hydrochloride CR is under clinical development by RedHill Biopharma and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData, Phase II drugs for Irritable Bowel Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ondansetron hydrochloride CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ondansetron hydrochloride CR overview
Ondansetron hydrochloride (RHB-102, Bekinda) is under development for the treatment of acute gastroenteritis, gastritis, diarrhea-predominant irritable bowel syndrome (IBS-D). The drug candidate is administered orally as a tablet. It is a once daily controlled release proprietary formulation of ondansetron. The drug candidate is developed based on CDT (Controlled Delivery Technology) technology. It was also under development for the treatment of radiotherapy induced nausea and vomiting (RINV) and chemotherapy-induced nausea and vomiting (CINV). It is a controlled release formulation.
RedHill Biopharma overview
RedHill Biopharma (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutinomeprazole; naloxegol; and rifamycin. It is investigating its pipeline candidates for the treatment of Crohn’s disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel coronavirus disease (COVID-19). The company has a subsidiary in the US. RedHill is headquartered in Tel Aviv, Israel.
For a complete picture of Ondansetron hydrochloride CR’s drug-specific PTSR and LoA scores, buy the report here.